Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BEBT 730

Next Previous
Drug Profile

BEBT 730

Alternative Names: BEBT-730

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeBetter Med
  • Class Antigouts; Small interfering RNA; Uricosurics
  • Mechanism of Action RNA interference; SLC22A12 protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gout; Hyperuricaemia

Most Recent Events

  • 22 Jan 2025 Pharmacodynamics data from preclinical studies in Gout and Hyperuricemia released by BeBetter Med
  • 19 Dec 2024 BEBT 730 is available for licensing as of 19 Dec 2024. http://www.bebettermed.com/goods-2-view.html
  • 19 Dec 2024 Preclinical trials in Gout in China (Parenteral) prior to December 2024 (BeBetter Med pipeline, January 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top